rss icon

KALAMAZOO — Armune BioScience Inc.’s sale to a Wisconsin company provides another exit for investors that generates returns they can use in future deals for life sciences startups in Michigan.

Published in Health Biz

 

The availability of scientific and executive management talent and the access to later-stage investment capital remain major issues for Michigan’s life sciences industry.

Published in Life Sciences

At some point in the coming months, Mark Gurney and directors at Tetra Discovery Partners LLC will decide which road to travel into the future for their company.

Published in Life Sciences

An agreement with a Canadian company will significantly expand sales and marketing efforts for Armune Bioscience Inc. and its new blood test for prostate cancer that hit the market this year. Under the co-marketing deal, Quebec City-based Aeterna Zenteris Inc. will market Armune’s Apifiny blood test alongside its own products as it meets with health systems and large medical groups across the U.S. 

Published in Health Biz

After naming a new CEO and CFO last month and closing on the first round of a $2.5 million capital raise, Armune BioScience Inc. aims to move into the marketplace this spring with a new-generation blood test for men suspected of having prostate cancer.

Published in Life Sciences

Breaking News

August 2018
S M T W T F S
29 30 31 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 1

Follow MiBiz